Effect of Efpeglenatide on Cardiovascular Outcomes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4076 participants.
Also called NCT03496298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,076 participants
- Registry
-
NCT03496298 -
2017-002954-35
-
- Other papers using this trial's data
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
- Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Bulgaria, Canada, Chile, Denmark, Estonia, Finland, Germany, Hungary, India, Italy, Latvia, Lithuania, Mexico, Norway, Peru, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Türkiye, Ukraine
- Registry status
- Terminated
Technical summary
Registry record NCT03496298. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-27 (actual); primary completion 2020-12-10 (actual). Results posted on 2021-10-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Efpeglenatide on Cardiovascular Outcomes
- Acronym
- AMPLITUDE-O
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Efpeglenatide (SAR439977)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sanofi
- Collaborator
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct03496298- Content hash
163607ba9df575dabd5f362763a82e5aae9a709cb9e4da48f1e3c5ad7754fc0f